| Maple Grove Health And Rehabilitation Center | |
| 308 West Meadowview Road, Greensboro, North Carolina 27406 | |
| (336) 230-0534 | |
| Name | Maple Grove Health And Rehabilitation Center |
|---|---|
| Location | 308 West Meadowview Road, Greensboro, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 210 |
| Occupancy Rate | 55.24% |
| Medicare ID (CCN) | 345448 |
| Legal Business Name | Snowshoe Ltc Group, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1326074048 |
| Organization Name | SNOWSHOE LTC GROUP, LLC |
| Doing Business As | MAPLE GROVE HEALTH AND REHABILITATION CENTER |
| Address | 308 W Meadowview Rd, Greensboro, NC 27406 |
| Phone Number | 336-230-0534 |
News Archive
Arthritis affects more than half of adults with heart disease and appears to be a substantial barrier to utilizing physical activity to help manage their condition, according to a new Morbidity and Mortality Weekly Report (MMWR) study released by the Centers for Disease Control and Prevention (CDC).
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
The Department of Homeland Security Science and Technology Directorate today announced the release of two ambulance safety resources for emergency medical services (EMS) leaders, professionals and organizations nationwide.
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Arthritis affects more than half of adults with heart disease and appears to be a substantial barrier to utilizing physical activity to help manage their condition, according to a new Morbidity and Mortality Weekly Report (MMWR) study released by the Centers for Disease Control and Prevention (CDC).
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
The Department of Homeland Security Science and Technology Directorate today announced the release of two ambulance safety resources for emergency medical services (EMS) leaders, professionals and organizations nationwide.
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $21334 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 30.24 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.8 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50.28 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.8 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.06 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 68.64 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.06 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 12.88 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.05 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 40.62 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.35 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.94 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.07 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 51.71 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 27.33 | 82.93 |
News Archive
Arthritis affects more than half of adults with heart disease and appears to be a substantial barrier to utilizing physical activity to help manage their condition, according to a new Morbidity and Mortality Weekly Report (MMWR) study released by the Centers for Disease Control and Prevention (CDC).
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
The Department of Homeland Security Science and Technology Directorate today announced the release of two ambulance safety resources for emergency medical services (EMS) leaders, professionals and organizations nationwide.
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.
› Verified 1 days ago
Blumenthal Nursing & Rehabilitation Center Location: 3724 Wireless Drive, Greensboro, North Carolina 27455 Phone: (336) 540-9991 | |
Accordius Health At Greensboro, Llc Location: 1201 Carolina Street, Greensboro, North Carolina 27401 Phone: (336) 522-5700 | |
Carolina Pines At Greensboro, Llc Location: 109 S Holden Rd, Greensboro, North Carolina 27407 Phone: (336) 522-5600 | |
Greenhaven Health And Rehabilitation Center Location: 801 Greenhaven Drive, Greensboro, North Carolina 27406 Phone: (336) 292-8371 | |
Friends Homes At Guilford Location: 925 New Garden Road, Greensboro, North Carolina 27410 Phone: (336) 292-8187 | |
Kindred Hospital East Greensboro Location: 2401 South Side Boulevard, Greensboro, North Carolina 27406 Phone: (336) 271-2800 |